(Q42643131)

4 November 2017

0 references

PCSK9 inhibitors--past, present and future (English)

1 reference

4 November 2017

Željko Reiner

1

1 reference

4 November 2017

language of work or name

English

0 references

publication date

2 September 2015

1 reference

Expert Opinion on Drug Metabolism & Toxicology

4 November 2017

published in

1 reference

4 November 2017

volume

11

1 reference

4 November 2017

issue

10

1 reference

4 November 2017

page(s)

1517-1521

1 reference

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075506

Statins in the primary prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075506

Prevalence and types of persistent dyslipidemia in patients treated with statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075506

The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075506

A comparison of European and US guidelines for familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075506

Resistance and intolerance to statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075506

Adverse effects of statins - myths and reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075506

Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075506

Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075506

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075506

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075506

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075506

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075506

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075506

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075506

Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075506

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075506

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075506

Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1075506

10.1517/17425255.2015.1075506

21 January 2018

Identifiers

DOI

1 reference

4 November 2017

1 reference